The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Dysfunctional HDL and atherosclerotic cardiovascular disease
Open accessAbstract
High-density lipoproteins (HDLs) protect against atherosclerosis by removing excess cholesterol from macrophages through the ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1) pathways involved in reverse cholesterol transport. Factors that impair the availability of functional apolipoproteins or the activities of ABCA1 and ABCG1 could, therefore, strongly influence atherogenesis. HDL also inhibits lipid oxidation, restores endothelial function, exerts anti-inflammatory and antiapoptotic actions, and exerts anti-inflammatory actions in animal models. Such properties could contribute considerably to the capacity of HDL to inhibit atherosclerosis. Systemic and vascular inflammation has been proposed to convert HDL to a dysfunctional form that has impaired antiatherogenic effects. A loss of anti-inflammatory and antioxidative proteins, perhaps in combination with a gain of proinflammatory proteins, might be another important component in rendering HDL dysfunctional. The proinflammatory enzyme myeloperoxidase induces both oxidative modification and nitrosylation of specific residues on plasma and arterial apolipoprotein A-I to render HDL dysfunctional, which results in impaired ABCA1 macrophage transport, the activation of inflammatory pathways, and an increased risk of coronary artery disease. Understanding the features of dysfunctional HDL or apolipoprotein A-I in clinical practice might lead to new diagnostic and therapeutic approaches to atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some studies have indicated a complete loss of function and dysfunction gain concerning anti-inflammatory, vasodilatory, and antiapoptotic activities.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, there are instances where HDL’s ability to deliver cholesterol esters via SCARB1 may be reduced, indicating only a partial loss of function.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“It was noted that HDL could lose its anti-inflammatory properties and even develop proinflammatory characteristics.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, when it comes to antioxidative activity and cholesterol efflux capacity, the deficiency observed in HDL’s normal function falls short of complete dysfunction [9].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Subsequent research has shown that the extent of HDL’s normal function loss and dysfunction gain can vary depending on its different biological activities.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Dysfunctional HDL (dys-HDL) are HDL cholesterol particles with high pro-atherogenic characteristics, characterized by the loss of typical antioxidant properties, becoming carriers of oxidized lipids themselves.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
In the citing paper
“Moreover, modulations in HDL particle composition can transform it to dysfunctional and, through this modulation, increase the risk of CVD40.”
From Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses (2016) · cites this paper as [40]
In the citing paper
“Decrease in HDL has been regarded as one important risk factor for cardiovascular diseases40.”
From Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses (2016) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationWiller (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationCholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Large-scale association analysis identifies new risk loci for coronary artery disease
The CARDIoGRAMplusC4D Consortium, Deloukas, P., DIAGRAM Consortium, CARDIOGENICS Consortium, MuTHER Consortium, Wellcome Trust Case Control Consortium, Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2480 · Cited by 1,614
HDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390
Daugherty, A., Dunn, J. L., Rateri, D. L., & Heinecke, J. W. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117342 · Cited by 1,269
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 821
Li, Z., Zheng, D., Zhang, T., Ruan, S., Li, N., Yang, Y., Yang, P., & Wang, D. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000343 · Cited by 20
Morgantini, C., Trifirò, S., Tricò, D., Meriwether, D., Baldi, S., Mengozzi, A., Reddy, S. T., & Natali, A. (2018) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.03.005 · Cited by 17
Yan, Y., He, F., Li, Z., Xu, R., Li, T., Su, J., Liu, X., Zhao, M. F., & Wu, W. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.11.016 · Cited by 18
Devarajan, A., & Vaseghi, M. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101810 · Cited by 18
Mendelian randomization under the omnigenic architecture
Wang, L., Gao, B., Fan, Y., Xue, F., & Zhou, X. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab322 · Cited by 14
miRNAs and High-Density Lipoprotein metabolism
Baldán, Á., & Vallim, T. Q. D. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.01.021 · Cited by 18
Chen, L., Ma, W., Chen, D., Wang, C., Gao, Y., & Ran, X. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001544 · Cited by 16
Foetal lipoprotein oxidation and preeclampsia
Gil-Acevedo, L., Ceballos, G. M., & Torres-Ramos, Y. D. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01663-5 · Cited by 17
Keul, P., Peters, S., Lipinski, K. V. W., Schröder, N. H., Nowak, M. K., Duse, D. A., Polzin, A., Weske, S., Gräler, M. H., & Levkau, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179606 · Cited by 16
de Azúa-López, Z. R., Pezzotti, M. R., González-Díaz, Á., Meilhac, O., Ureña, J., Amaya‐Villar, R., Castellano, A., & Varela, L. M. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231184806 · Cited by 16
High-density lipoprotein regulates angiogenesis by affecting autophagy via miRNA-181a-5p
Kang, B.-A., Li, H.-M., Chen, Y.-T., Deng, M.-J., Li, Y., Peng, Y.-M., Gao, J.-J., Mo, Z.-W., Zhou, J., Ou, Z., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2381-7 · Cited by 16
Chen, D.-L., Chung, C., Wang, G., & Chang, K. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.06.029 · Cited by 16
Soupène, E., Borja, M. S., Borda, M., Larkin, S. K., & Kuypers, F. A. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216657447 · Cited by 16
Association Between HDL Cholesterol and QTc Interval: A Population-Based Epidemiological Study
Giorno, R. D., Gabutti, S., Troiani, C., Stefanelli, K., Falciano, R., Graziano, E., Negro, T. R., & Gabutti, L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101527 · Cited by 16
High Free Cholesterol Bioavailability Drives the Tissue Pathologies in Scarb1 −/− Mice
Liu, J., Gillard, B. K., Yelamanchili, D., Gotto, A. M., Rosales, C., & Pownall, H. J. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316535 · Cited by 16
Flaherty, S., Wood, E. K., Ryff, C. D., Love, G. D., Kelesidis, T., Berkowitz, L., Echeverría, G., Rivera, K., Rigotti, A., & Coe, C. L. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-021-01608-4 · Cited by 16
Wu, Y., Xu, Y., Chen, J., Zhao, M., & Rye, K. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-1592-5_3 · Cited by 17
Liu, M., Liu, X., Wei, Z., Hua, R., Huang, Y., Hao, X., Yuan, Z., & Zhou, J. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002314 · Cited by 15
Zhang, L., Zhang, W., He, L., Cui, H., Wang, Y., Wu, X., Zhao, X., Yan, P., Yang, C., Xiao, C., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03072-6 · Cited by 15
Kazenwadel, J., Berezhnoy, G., Cannet, C., Schäfer, H., Geisler, T., Rohlfing, A., Gawaz, M., Merle, U., & Trautwein, C. (2023) · Communications Medicine · doi:10.1038/s43856-023-00365-y · Cited by 15
Evaluate the Relationship Between Obstructive Sleep Apnea and Metabolic Syndrome in Real-World Data
Tang, R., Li, C., Di, D., Zhou, L., Qian, Y., Qiang, C., Ma, C., Zhou, R., Wang, B., & Min, W. Z. (2024) · Nature and Science of Sleep · doi:10.2147/nss.s433514 · Cited by 17
Lipoproteins and Cardiovascular Redox Signaling: Role in Atherosclerosis and Coronary Disease
Haghikia, A., & Landmesser, U. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7052 · Cited by 16
Giudice, R. D., Nilsson, O., Domingo‐Espín, J., & Lagerstedt, J. O. (2017) · Scientific Reports · doi:10.1038/s41598-017-13878-z · Cited by 15
Shi, W., Wang, H., Chen, S., Guo, X., Zhao, L., & Sun, Y. (2019) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0406 · Cited by 15
Sex Difference Impacts on the Relationship between Paraoxonase-1 (PON1) and Type 2 Diabetes
Rosta, V., Trentini, A., Passaro, A., Zuliani, G., Sanz, J. M., Bosi, C., Bonaccorsi, G., Bellini, T., & Cervellati, C. (2020) · Antioxidants · doi:10.3390/antiox9080683 · Cited by 15
Huang, J., Tao, H., Yancey, P. G., Leuthner, Z., Zhang, L., Jung, J., Zhang, Y., Ding, L., Amarnath, V., Liu, D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101651 · Cited by 15
Durrington, P. N., Bashir, B., & Soran, H. (2025) · Antioxidants · doi:10.3390/antiox14040430 · Cited by 19
Pig and Mouse Models of Hyperlipidemia and Atherosclerosis
Getz, G. S., & Reardon, C. A. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_24 · Cited by 14
Lee, M., Lim, J., Kim, Y., Park, S. H., Lee, S., Kim, C., Lee, B., Yu, K., Lee, J. J., & Oh, M. S. (2023) · Nutrients · doi:10.3390/nu15214670 · Cited by 15
Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis
Lin, Y., Lin, R., Lin, H.-B., & Shen, S. (2024) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2024.100189 · Cited by 14
Andersen, C. J., & Fernández, M. L. (2024) · Nutrients · doi:10.3390/nu17010042 · Cited by 14
Zheng, W., Lai, Y., Jin, P., Gu, W., Zhou, Q., & Wu, X. (2017) · Disease Markers · doi:10.1155/2017/1917291 · Cited by 14
Xu, P., & Wang, J. (2019) · Journal of Endourology · doi:10.1089/end.2019.0404 · Cited by 14
Sadana, P., Lin, L., Aghayev, M., Ilchenko, S., & Kasumov, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207472 · Cited by 14
Jin, Z., Lan, Z., Tian, R., & Lu, N. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00086 · Cited by 14
Large-Scale Analysis of Apolipoprotein CIII Glycosylation by Ultrahigh Resolution Mass Spectrometry
Demus, D., Naber, A., Dotz, V., Jansen, B. C., Bladergroen, M. R., Nouta, J., Sijbrands, E. J. G., van Hoek, M., Nicolardi, S., & Wuhrer, M. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.678883 · Cited by 14
Chauhan, A. S., Patel, A. K., Nimker, V., Singhania, R. R., Chen, C., Patel, A., Raj, T., & Dong, C. (2023) · Systems Microbiology and Biomanufacturing · doi:10.1007/s43393-023-00207-x · Cited by 14
Rosoff, D. B., Charlet, K., Jung, J., Lee, J., Muench, C., Luo, A. C., Longley, M. J., & Lohoff, F. W. (2020) · Alcohol · doi:10.1016/j.alcohol.2020.02.164 · Cited by 14
Kurakin, A. V., & Bredesen, D. E. (2020) · Aging · doi:10.18632/aging.103883 · Cited by 15
Bergougnan, L., Andersen, G., Plum‐Mörschel, L., Evaristi, M. F., Poirier, B., Tardat, A., Ermer, M., Herbrand, T., Arrubla, J., Coester, H. V., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14632 · Cited by 14
Tao, X., He, J., Zhang, Y., Yin, Y., Yang, C. G., Shang, Y., & Wu, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.06.018 · Cited by 13
Is there a potential of circulating miRNAs as biomarkers in rheumatic diseases?
Prajzlerová, K., Šenolt, L., & Filková, M. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.08.011 · Cited by 13
Elevated Lp(a) Levels Correlate with Severe and Multiple Coronary Artery Stenotic Lesions
Hageh, C. A., Chacar, S., Ghassibe‐Sabbagh, M., Platt, D. E., Henschel, A., Hamdan, H., Gauguier, D., Murr, Y. E., Alefishat, E. A., Chammas, E., et al. (2023) · Vascular Health and Risk Management · doi:10.2147/vhrm.s394134 · Cited by 13
Graham, A. (2023) · Biology · doi:10.3390/biology12091232 · Cited by 14
Apolipoprotein A-1 Accelerated Liver Regeneration Through Regulating Autophagy Via AMPK-ULK1 Pathway
Wang, Z., Chen, R. X., Wang, J. F., Liu, S. C., Xu, X., Zhou, T., Chen, Y. A. L., Zhang, Y. D., Li, X. C., & Li, C. X. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.12.004 · Cited by 14
Chen, C., Chang, C., Lee, I., Huang, C.-Y., Lin, F., Lin, S., Chen, J., & Chang, T. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2296184 · Cited by 14
Grote, K., Schaefer, A.-C., Soufi, M., Ruppert, V., Linne, U., Bhagwat, A. M., Szymanski, W. G., Graumann, J., Gercke, Y., Aldudak, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084522 · Cited by 12
Pardina, E., Ferrer, R., Rossell, J., Ricart-Jané, D., Méndez‐Lara, K. A., Baena‐Fustegueras, J. A., Lecube, A., Julve, J., & Peinado‐Onsurbe, J. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.115 · Cited by 13
E3317 promotes cholesterol efflux in macrophage cells via enhancing ABCA1 expression
Wang, X., Luo, J., Li, N., Liu, L., Han, X., Liu, C., Zuo, X., Jiang, X., Li, Y., Xu, Y., et al. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.08.125 · Cited by 13
Xu, Y., Li, F., Zhao, X., Tan, C., Wang, B., Chen, Y., Cao, J., Wu, D., & Yu, H. (2020) · The FASEB Journal · doi:10.1096/fj.201902429r · Cited by 13
Zhou, Y., Fang, X., Zhang, Y., Feng, Y., & Wang, S. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22589 · Cited by 13
Mahrooz, A., Shokri, Y., Variji, A., Zargari, M., Alizadeh, A., & Mehtarian, E. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.12.026 · Cited by 13
Hypercholesterolemia and Lymphatic Defects: The Chicken or the Egg?
Miyazaki, T., & Miyazaki, A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.701229 · Cited by 13
Zhao, X., Liu, L., Guo, C., Shen, W.-W., Cao, J., Du, F., Wu, D., & Yu, H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-682 · Cited by 13
Luo, T., Liu, D., Guo, Z., Chen, P., Guo, Z., Ou, C., & Chen, M. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.05.013 · Cited by 13
Xiao, W., Li, J., Huang, X., Zhu, Q. K., Liu, T., Xie, H., Deng, Z., & Tang, Y. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2077427 · Cited by 13
Khattib, A., Musa, S., Halabi, M., Hayek, T., & Khatib, S. (2022) · Antioxidants · doi:10.3390/antiox11102058 · Cited by 13
Klobučar, I., Stadler, J. T., Klobučar, L., Lechleitner, M., Trbušić, M., Pregartner, G., Berghold, A., Habisch, H., Madl, T., Marsche, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032073 · Cited by 13
Tan, L., Ouyang, Z., Chen, Z., Sun, F., Guo, H., Wang, F., Mulder, M. T., Sun, Y., Lu, X., Zhang, J. V., et al. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01777-4 · Cited by 13
Lövgren, J., Pursiheimo, J., Pyykkö, M., Salmi, J., & Lamminmäki, U. (2016) · New Biotechnology · doi:10.1016/j.nbt.2016.07.009 · Cited by 13
Serum inhibitory factor 1, high-density lipoprotein and cardiovascular diseases
Martinez, L. O., Genoux, A., Ferrières, J., Duparc, T., & Perret, B. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000434 · Cited by 13
Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?
Satta, N., Frias, M. A., Vuilleumier, N., & Pagano, S. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190830164917 · Cited by 14
Dergunova, L. V., Nosova, E. V., Dmitrieva, V. G., Rozhkova, A. V., Bazaeva, E. V., Limborska, S. A., & Dergunov, A. D. (2019) · Journal of Medical Biochemistry · doi:10.2478/jomb-2019-0052 · Cited by 13
Sucato, V., Comparato, F., Ortello, A., Galassi, A. R., & Novo, G. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14050460 · Cited by 12
Plasma apoM Levels and Progression to Kidney Dysfunction in Patients With Type 1 Diabetes
Baker, N. L., Hammad, S. M., Hunt, K. J., Semler, A. J., Klein, R. L., & Lopes-Virella, M. F. (2022) · Diabetes · doi:10.2337/db21-0920 · Cited by 12
Plasma Cell-Free DNA as a Novel Biomarker for the Diagnosis and Monitoring of Atherosclerosis
Qian, B., Li, K., Lou, X., Guo, Y., Wang, Y., Wu, L., & Zhang, D. (2022) · Cells · doi:10.3390/cells11203248 · Cited by 12
Yan, S., Sha, S., Wang, D., Li, S., & Jia, Y. (2022) · Coronary Artery Disease · doi:10.1097/mca.0000000000001208 · Cited by 12
Rosenson, R. S., & Köenig, W. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6642-9 · Cited by 12
Self-citationABCA1 genetic polymorphisms and type 2 diabetes mellitus and its complications
Haerian, B. S., Haerian, M. S., Roohi, A., & Mehrad‐Majd, H. (2017) · Meta Gene · doi:10.1016/j.mgene.2017.05.007 · Cited by 12
Hsu, C.-P., Lin, C., & Kuo, C. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.24659 · Cited by 12
The Alcohol–High-Density Lipoprotein Athero-Protective Axis
Rosales, C., Gillard, B. K., Gotto, A. M., & Pownall, H. J. (2020) · Biomolecules · doi:10.3390/biom10070987 · Cited by 13
Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice
Morin, E. E., Guo, Y., He, H., Yuan, W., Souery, W. N., Fawaz, M. V., Chen, Y. E., & Schwendeman, A. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.513031 · Cited by 12
Genetic variations in ABCA1/G1 associated with plasma lipid levels and risk of ischemic stroke
Yang, S., Jia, J., Yang, L., Li, Z., Li, Z., Zhang, Z., Zhou, B., Luan, Y., Huang, Y., Peng, Y., et al. (2022) · Gene · doi:10.1016/j.gene.2022.146343 · Cited by 12
Zhao, L., Liu, Y., Xiao, J.-Y., Wang, J.-X., Li, X., Cui, Z., & Gao, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.912999 · Cited by 12
Zhou, P., Kang, J.-L., Cheng, Q., Chen, M., Xie, Y., & Zhou, H. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154305 · Cited by 12
Nessler, K., Grzybczak, R., Nessler, M. B., Zalewski, J., Gajos, G., & Windak, A. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02928-8 · Cited by 12
Yamada, H., Umemoto, T., Kawano, M., Kawakami, M., Kakei, M., Momomura, S., Ishikawa, S., & Hara, K. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.01.138 · Cited by 14
Dopico, A. M., & Bukiya, A. N. (2017) · Current topics in membranes · doi:10.1016/bs.ctm.2017.07.001 · Cited by 13
Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease
Girón, G. O., Otero, S., Nikolaou, P., Alcover, S., Ramos-Regalado, L., Zaragoza, C., Liberale, L., Borrell-Pagés, M., Padró, T., Suades, R., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70167 · Cited by 12
High-Density Lipoprotein and Cardiovascular Disease—Where do We Stand?
Iatan, I., Choi, H. Y., & Genest, J. J. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.01.003 · Cited by 11
Dong, H., Wang, J., Hu, P. F., & Lu, N. (2022) · Angiology · doi:10.1177/00033197221121002 · Cited by 11
Islam, M. N., Mishra, V. K., Munalisa, R., Parveen, F., Ali, S. F., Akter, K., Ahmed, T., Ho, T., & Huang, C. (2024) · Molecular & Cellular Toxicology · doi:10.1007/s13273-023-00424-4 · Cited by 11
Atherogenic circulating lipoproteins in ischemic stroke
Benı́tez, S., Puig, N., Camps‐Renom, P., & Sánchez‐Quesada, J. L. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1470364 · Cited by 11
Dong, G.-X., Li, W., Wang, R.-Z., Zou, W., Zhong, Z. A., & Li, B. (2017) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000500 · Cited by 11
Barbosa, C., Maranhão, R. C., Barreiros, R. S., Freitas, F. R., Franci, A., Strunz, C. M. C., Arantes, F. B. B., Tavoni, T. M., Ramires, J. A. F., Filho, R. K., et al. (2019) · Clinical Cardiology · doi:10.1002/clc.23259 · Cited by 11
Yang, T., Wan, K., Song, R., Guo, X., Xu, Y., Wang, J., Zhang, Q., Alexander, K. M., Liao, R., & Chen, Y. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.10.034 · Cited by 11
Wu, T., Zheng, Y., Xiu, W., Wang, W.-R., Xun, Y.-L., Ma, H., Kadir, P., Pan, Y., Ma, Y., & Xie, X. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.616896 · Cited by 11
Mizuguchi, C., Nakamura, M., Kurimitsu, N., Ohgita, T., Nishitsuji, K., Baba, T., Shigenaga, A., Shimanouchi, T., Okuhira, K., Otaka, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23920-3 · Cited by 12
Liu, J., Zhao, M., Zhu, Y., Wang, X., Zheng, L., & Yin, Y. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00290 · Cited by 12
Impact of 5-week high-intensity interval training on indices of cardio metabolic health in men
Lira, F. S., Antunes, B. M., Figueiredo, C., Campos, E. Z., Panissa, V. L. G., St-Pierre, D. H., Lavoie, J.-M., & Tomaz, L. M. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.02.006 · Cited by 12
Li, W., Liu, X., Huang, C., Liu, L., Tan, X., & Wang, X. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.10.019 · Cited by 12
Alışık, T., Alışık, M., Nacir, B., Ayhan, F. F., Genç, H., & Erel, Ö. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14172 · Cited by 11
Scavenger Receptor BI Induced by HDL From Coronary Heart Disease May Be Related to Atherosclerosis
Fen, G., Feng, G.-J., Li, H., Qin, W.-W., & Chuan-shi, X. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211029710 · Cited by 10
Yao, X., Kaler, M. M., Qu, X., Kalidhindi, R. S. R., Sviridov, D. O., Dasseux, A., Barr, E. W., Keeran, K. J., Jeffries, K. R., Yu, Z., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.11.917 · Cited by 10
Chen, Y., Lan, X., Han, J., Xiang, X., Li, Q., Xu, X., Wang, T., Huang, S., Shen, J., & Ma, X. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102553 · Cited by 10
Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature
Sheashaa, H., Mousa, H., Abbas, M. T., Farina, J., Awad, K., Pereyra, M., Scalia, I. G., Ali, N. B., Javadi, N., Bismee, N. N., et al. (2025) · Biomolecules · doi:10.3390/biom15020162 · Cited by 11
Machine learning-based coronary heart disease diagnosis model for type 2 diabetes patients
Chen, Y., Wang, C., Liu, X., Duan, M., Xiang, T., & Huang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1550793 · Cited by 10
Sharifi‐Zahabi, E., Nasiri, N., Hajizadeh‐Sharafabad, F., Mohammadi, S., Shahbazi, S., & Salehi, N. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02620-8 · Cited by 10
Miura, K., Arai, N., Goka, R., Morimoto, N., Watanabe, S., Isoda, N., Yamamoto, H., & Kotani, K. (2021) · Antioxidants · doi:10.3390/antiox10020239 · Cited by 10
Tomić, M., Vrabec, R., Bulum, T., & Ljubić, S. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109814 · Cited by 10
Metadata
- Authors
- Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- MedStar Washington Hospital Center (US)
- University of California, Los Angeles (US)
- UNSW Sydney (AU)
- Inserm (FR)
- University of Washington (US)
- Columbia University (US)
- University of Kentucky (US)
- Corresponding author
- Rosenson, Robert S.
- Venue
- Nature Reviews Cardiology
- Published
- 2015-09-01
- Volume
- 13
- Issue
- 1
- Pages
- 48-60
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- PMC
- PMC6245940
- OpenAlex
- W2175680864
- Cited by
- 822
- References
- 131
- Citations by year
- 2026: 89 · 2025: 89 · 2024: 66 · 2023: 79 · 2022: 86 · 2021: 79 · 2020: 79 · 2019: 62 · 2018: 69 · 2017: 61 · 2016: 56 · 2015: 5
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DP3DK108209, P30DK017047)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- HDL dysfunction, atherosclerosis, apolipoprotein A-I, reverse cholesterol transport, ABCA1, ABCG1, myeloperoxidase, nitrosylation, oxidative modification, inflammation, endothelial function, coronary artery disease, atherogenesis, anti-inflammatory activity
- MeSH terms
- Humans, Lipoproteins, HDL, Macrophages, Smoking, Apolipoprotein A-I, ATP-Binding Cassette Transporters, Diabetes Complications, Atherosclerosis, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
